AI-Driven Next-Generation ADC Discovery
Integrating artificial intelligence, molecular dynamics, and biophysics to accelerate the design of next-generation antibody–drug conjugates (ADCs) for oncology.
From Intelligence to Therapeutic Design.
Our platform integrates AI, molecular dynamics and translational science to support the development of differentiated oncology therapeutics.
Science moves where ecosystems connect.
Wild Bird Therapeutics was built across scientific, technological, and entrepreneurial ecosystems.
We bring together global expertise to accelerate next-generation oncology innovation.
Our platform combines AI, molecular dynamics, and translational science to support the development of differentiated oncology therapeutics.
Global Scientific Network
We integrate world-class scientific talent across Europe, the U.S. and Asia to accelerate oncology innovation through cross-ecosystem collaboration.
AI-Enabled Discovery
Artificial intelligence supports target identification, molecular design and translational decision-making across our oncology development programs.
ADC Development Focus
Wild Bird Therapeutics focuses on the development of next-generation antibody-drug conjugates designed for differentiated oncology applications.
Strategic Asia Positioning
Positioned within Asia’s leading innovation corridor, we connect global science with translational infrastructure, capital and execution capabilities.
AI-Driven ADC Development Platform
Wild Bird Therapeutics focuses on the discovery and development of next-generation oncology therapeutics by integrating computational science with translational execution.
Our approach is designed to accelerate early-stage decision making, optimize development pathways and reduce inefficiencies across the ADC discovery process.
Lead ADC Program
Wild Bird Therapeutics is advancing its lead ADC program through the integration of AI-driven discovery, molecular dynamics and translational oncology science.
The asset has demonstrated encouraging preclinical in vivo activity, supporting its continued development as a differentiated next-generation oncology therapeutic candidate.
As the company’s most advanced ADC program, it reflects Wild Bird Therapeutics’ strategy of combining computational innovation, global scientific expertise and translational execution across the therapeutic development process.
News
WBT Engages with Leading Scientific and Life Sciences Institutions in Shenzhen
Wild Bird Therapeutics Hong Kong Limited participated in a strategic discussion session with Shenzhen Bay Laboratory during its visit to Guangming Science City, one of Shenzhen’s key hubs for biomedical research and life sciences innovation. The program also included…
Wild Bird Therapeutics Presents Its Vision to Spanish Business Delegation in Hong Kong
Wild Bird Therapeutics Hong Kong Limited had the opportunity to present its company, mission and strategic vision to a delegation of Spanish entrepreneurs, executives and professionals visiting Hong Kong and Shenzhen as part of an innovation program led by Eseune…
Wild Bird Therapeutics Selected for HSITP IGNITE Programme
Wild Bird Therapeutics has been selected to join the IGNITE programme from Hong Kong-Shenzhen Innovation and Technology Parks (HSITP), supporting the company’s international expansion and the development of its AI-enabled oncology and ADC innovation platform within…